Multimodality imaging of tumor integrin alphavbeta3 expression
1Molecular Imaging Program at Stanford, MIPS, Department of Radiology, Stanford University, CA 94305, USA. shawchen@stanford.edu
Abstract:
Most solid tumors are angiogenesis dependent. Anti-angiogenic pharmaceuticals that inhibit the growth of new blood vessels offer considerable promise as anti-cancer agents. With increasing numbers of anti-angiogenic drugs in clinical trials, there is an urgent need for detailed characterization of the heterogeneity of tumor vasculature and dissection of the complex network of mechanisms that control tumor angiogenesis. Non-invasive molecular imaging will play a key role in individualized anti-angiogenic therapy based upon molecular features of the new blood vessel growth. Integrin alpha(v)beta(3), which binds several ligands via an RGD tripeptide sequence, is uniquely expressed in tumor vasculature and aggressive tumor cells, making it a potential target for anti-angiogenic interventions. This review highlights some recent advances in multimodality imaging of tumor integrin expression with emphasis on positron emission tomography (PET).
Insights
Targeting tumor blood vessel growth (angiogenesis) shows promise for cancer treatment. Molecular imaging, particularly positron emission tomography (PET), can help personalize anti-angiogenic therapies by visualizing specific molecular targets like integrin alpha(v)beta(3).
Area of Science:
- Oncology
- Molecular Imaging
- Vascular Biology
Background:
- Solid tumors rely on angiogenesis for growth.
- Anti-angiogenic drugs are a promising cancer therapy approach.
- Understanding tumor vasculature heterogeneity is crucial for effective treatment.
Purpose of the Study:
- To review advances in multimodality imaging of tumor integrin expression.
- To highlight the role of molecular imaging in anti-angiogenic therapy.
- To focus on positron emission tomography (PET) for integrin imaging.
Main Methods:
- Review of current literature on tumor angiogenesis and imaging.
- Discussion of integrin alpha(v)beta(3) as a molecular target.
- Emphasis on positron emission tomography (PET) techniques.
Main Results:
- Integrin alpha(v)beta(3) is a key target expressed in tumor vasculature.
- Non-invasive molecular imaging enables characterization of tumor angiogenesis.
- PET imaging offers potential for personalized anti-angiogenic strategies.
Conclusions:
- Molecular imaging is vital for tailoring anti-angiogenic therapies.
- Targeting integrin alpha(v)beta(3) with imaging agents is a promising strategy.
- Further development of PET imaging is essential for clinical application.
